98%
921
2 minutes
20
Introduction: Low back pain (LBP), a global disability leader, is often linked to intervertebral disc (IVD) degeneration. Traditional diagnostics like T2-weighted MRI provide qualitative but imprecise evaluations. A novel post-processing MRI technique, Decay Variance (DeVa), has shown promise in differentiating degenerate from healthy discs in animal studies. DeVa quantifies IVD degeneration by analyzing variations in signal intensities within each voxel in a T2* 2D FLASH multi-echo MRI sequence. This study aimed to validate DeVa clinically and explore its correlation with pain severity.
Methods: A cross-sectional study included 77 chronic LBP patients and 8 controls, who underwent T2-weighted and T2* 2D FLASH MRI. DeVa scores (worst and sum of all discs) were recorded, alongside traditional assessments like disc bulge, stenosis, high-intensity zones, and Pfirrmann grade. Pain severity was measured with a numerical rating scale. Statistical analyses included Pearson correlation, -tests, and Gardner-Altman plots to evaluate relationships between DeVa scores, degeneration, and pain.
Results: DeVa scores correlated strongly with Pfirrmann grade ( = 0.692, < 0.001) and were significantly higher in discs with bulge, stenosis, or high-intensity zones ( < 0.001). Moderate correlations were observed between worst DeVa scores ( = 0.296, < 0.01), total DeVa scores ( = 0.323, < 0.005) and pain severity. Patients with chronic LBP without severe degeneration (Pfirrmann ≤ 3 with no stenosis observable on standard MRI) had significantly higher worst (1.38 ± 0.26 vs. 1.10 ± 0.29, < 0.005) and total (5.39 ± 0.75 vs. 4.65 ± 0.61, < 0.0.1) DeVa scores compared to controls.
Discussion: DeVa offers a quantitative, noninvasive approach to assessing IVD degeneration, showing strong correlations with disc health and pain. It demonstrates enhanced sensitivity over traditional MRI, enabling the identification of pain-generating discs and informing personalized treatment strategies for chronic LBP. Further validation in larger populations is needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885163 | PMC |
http://dx.doi.org/10.1002/jsp2.70056 | DOI Listing |
Clin Exp Metastasis
September 2025
Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
Recent years have seen the development and advent of novel combinatorial strategies based on immunotherapy, and immune checkpoint inhibitor (ICI) - based treatment has established itself as a mainstay in the treatment of metastatic urothelial carcinoma (UC). Herein, we aimed to validate the prognostic value of a previously developed score, the Prognostic Immunotherapy Score (PIS), including female sex, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) and liver metastases, in patients treated with pembrolizumab for advanced UC from the ARON-2 dataset. We retrospectively analyzed clinical data from Metastatic UC patients diagnosed at age ≥ 18 years.
View Article and Find Full Text PDFEClinicalMedicine
September 2025
Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Background: Pressurised metered dose inhalers (pMDIs) contain a hydrofluorocarbon propellant, such as hydrofluoroalkane-134a (HFA-134a), which is known to have global warming potential (GWP). Transitioning pMDIs to propellants with lower GWP will reduce the environmental impact of pMDIs. This study assessed the safety of a near-zero GWP propellant, hydrofluoroolefin-1234ze (HFO-1234ze), compared with HFA-134a when used in the delivery of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) in participants with chronic obstructive pulmonary disease (COPD).
View Article and Find Full Text PDFCardiovasc Revasc Med
June 2025
Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Background: In-stent restenosis remains a persistent challenge in interventional cardiology. While both intravascular brachytherapy (IVB) and drug-coated balloons (DCB) have been used to treat this condition, their comparative effectiveness has never been evaluated.
Objectives: To compare the efficacy and safety of IVB versus DCB for the treatment of in-stent restenosis.
Respir Med
July 2025
GSK, Dubai, United Arab Emirates. Electronic address:
Background: Asthma affects over 260 million people globally, with significant health impacts. The Global Initiative for Asthma (GINA) 2024 report recommends inhaled corticosteroid/long-acting β-agonist (ICS/LABA) combinations, including fluticasone propionate/salmeterol (FP/SAL) and budesonide/formoterol (BUD/FOR), for maintenance treatment. Both combinations have demonstrated clinical benefits, with previous clinical trials and real-world studies showing comparable asthma control with FP/SAL and BUD/FOR.
View Article and Find Full Text PDFCurr Drug Saf
April 2025
Department of Pharmacy Practice, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education & Research, Belagavi, Karnataka, India.
Background: In India, the knowledge and perception of vaccine pharmacovigilance and adverse events following immunization (AEFI) reporting among pharmacy students are not clear.
Aim: This study aimed to evaluate the current knowledge and perceptions of vaccine pharmacovigilance and AEFI reporting among pharmacy students.
Method: An online cross-sectional survey was conducted for three months.